Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1985368 | 0.87 | SMN1; SMN2 (0.35) | TYRSMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL1985371 | 0.87 | SMN1; SMN2 (0.35) | TYRSMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL8641759 | 0.85 | TAS1R3 (0.33) | TYRLMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL14862368 | 0.84 | TYR (0.34) | TYRALDH1A1MEN1KMT2A | |
| SCHEMBL12245282 | 0.84 | TYR (0.34) | TYRALDH1A1MEN1KMT2A | |
| SCHEMBL25413295 | 0.82 | DPP4 (0.35) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10308400 | 0.82 | DPP4 (0.35) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7061312 | 0.82 | PREP (0.44) | HTTALDH1A1MEN1KMT2ACTSL | |
| SCHEMBL6159871 | 0.82 | PREP (0.44) | HTTALDH1A1MEN1KMT2ACTSL | |
| SCHEMBL197689 | 0.82 | PREP (0.44) | HTTALDH1A1MEN1KMT2ACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2021-05-13 | — | — | US | disclosed |
| US-20180134717-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | PSMA2, PSMA7, FOLH1 | TYR 3357/4885LMNA 4039/4885SMN1; SMN2 3231/4885 |
| US-20180134717-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | HDAC10, PBDC1, PDCD10 | TYR 1604/4885LMNA 2456/4885SMN1; SMN2 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.